Kamada Ltd. KMDA
8.13 USD +0.03 (+0.37%)
At closeNov 12, 2026, 4:12 AM EST
8.14 +0.01 +0.12%
Pre-market · Nov 12, 4:12 AM ET
8.04 Day range 8.15
6.60 52-week range 9.35
- YTD
- +15.16%
- 1 year
- +11.68%
News
seekingalpha.com Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript
zacks.com Kamada (KMDA) Surpasses Q3 Earnings Estimates Kamada (KMDA) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
benzinga.com Kamada Q3 2026 Earnings Call Transcript Kamada (NASDAQ:KMDA) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Kamada Q3 EPS $0.14 Beats $0.13 Estimate, Sales $52.034M Miss $52.506M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.13 by 7.69 percent. This is a 55.56 percent increase over earnings of $0.09 per…
benzinga.com Kamada Raises FY2026 Sales Guidance from $200.000M-$205.000M to $205.000M-$208.000M vs $202.960M Est Kamada (NASDAQ:KMDA) raises FY2026 sales outlook from $200.000 million-$205.000 million to $205.000 million-$208.000 million vs $202.960 million estimate.
globenewswire.com Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027 REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for…
globenewswire.com Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
zacks.com Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Evaluate the expected performance of Kamada (KMDA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key…
benzinga.com Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…- benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
benzinga.com Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per…
benzinga.com Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026 Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…- benzinga.com Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
benzinga.com Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
benzinga.com Kamada Q1 2026 Earnings Call: Complete Transcript 
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $201.581M Est Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $201.581 million estimate.- benzinga.com Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is unchanged from the same period last year. The…
benzinga.com Kamada Secures Israeli Tax Ruling On $0.25 Dividend, Allowing Reduced Withholding For Nasdaq Treaty Shareholders Kamada Ltd. (the "Company") (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the…- benzinga.com Kamada Says FDA Approves Kamada Plasma's Collection Center In San Antonio San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated…
- benzinga.com Earnings Scheduled For March 11, 2026
- benzinga.com Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million.
- benzinga.com Kamada Q4 EPS $0.06 Misses $0.08 Estimate, Sales $44.678M Miss $45.422M Estimate Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 22.08 percent. This is a 14.29 percent decrease over earnings of $0.07 per…
benzinga.com What's Next: Kamada's Earnings Preview 
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For August 13, 2025 - benzinga.com Earnings Scheduled For May 14, 2025
- benzinga.com Earnings Scheduled For March 5, 2025
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com Earnings Scheduled For March 6, 2024 Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
- benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For May 24, 2023 Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 241 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 215 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Earnings Scheduled For March 15, 2022 Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.
- benzinga.com Earnings Scheduled For February 10, 2021 Companies Reporting Before The Bell • Advanced Energy Indus (NASDAQ:AEIS) is projected to report quarterly earnings at $1.35 per share on revenue of $364.66 million.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 127 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com Stocks Which Set New 52-Week High Yesterday, September 13th